ReviewClinical microbiology reviews2012
Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.
Review in Clinical microbiology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
250 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.The European respiratory journal · 2020Guideline
- The functional and catalytic landscape of urease reveals a conserved target againstGut microbes · 2026Article
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- A review of tigecycline resistance in nontuberculous mycobacteria.Molecular biology reports · 2026Review
- Effectiveness of mass spectrometry and genomic analysis in the surveillance of nontuberculousJournal of clinical microbiology · 2026Article
- Mycobacterium smegmatis Infection in a Cardiovascular Implantable Electronic Device in an Immunocompetent Patient.Cureus · 2026Article
- Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria.International journal of molecular sciences · 2026Review
- Utility of RGM medium for recovery ofIranian journal of microbiology · 2026Article
- Evaluation of the deeplex Myc-TB-targeted next-generation sequencing assay for mycobacterial identification and drug resistance detection.Journal of clinical microbiology · 2026Article
- Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacteriumabscessus.The Journal of biological chemistry · 2026Article
- Pulmonary Infection Caused by Mycolicibacterium neoaurum: The First Documented Case in Morocco.Cureus · 2026Article
- Detection of Nontuberculous Mycobacterial Skin Infection by Next-Generation Sequencing: A Pilot Study.Journal of clinical medicine · 2026Article
- Article
- Plasmid-mediated macrolide resistance among rapidly growing mycobacteria in Japan.JAC-antimicrobial resistance · 2026Article
- The first reported case ofASM case reports · 2026Article
- Bioactive potential of Pulicaria undulata from arid regions against multidrug-resistant pathogens and cancer cells.AMB Express · 2026Article
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Widespread macrolide resistance among rapidly growing mycobacteria due to plasmids containing erm(55).Scientific reports · 2026Article
- Emerging trends and structure-activity insights of Schiff base-lanthanide complexes as antibacterial agents.RSC advances · 2026Review
190 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the past 10 years, treatment and diagnostic guidelines for nontuberculous mycobacteria have been recommended by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Moreover, the Clinical and Laboratory Standards Institute (CLSI) has published and recently (in 2011) updated recommendations including suggested antimicrobial and susceptibility breakpoints. The CLSI has also recommended the broth microdilution method as the gold standard for laboratories performing antimicrobial susceptibility testing of nontuberculous mycobacteria. This article reviews the laboratory, diagnostic, and treatment guidelines together with established and probable drug resistance mechanisms of the nontuberculous mycobacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.